EUROPEAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION

Narsoplimab-treated TA-TMA patients showed a 3-fold reduction in mortality risk (HR=0.32, p<0.00001) compared to non-treated patients. Omeros plans to resubmit its BLA for narsoplimab as the first approved TA-TMA treatment.

Studies on multiple myeloma treatments include daratumumab, bortezomib, lenalidomide, and dexamethasone combinations, with varying outcomes reported in trials like GRIFFIN, CASSIOPEIA, and MAIA. Key findings include improved survival and response rates with autologous stem cell transplantation, particularly in high-risk patients, and the continued relevance of the International Scoring System (ISS) for prognostic assessment.

Tacrolimus and cyclosporine A are similarly effective in maintaining long-term survival and reducing relapse in AML patients post transplant, with tacrolimus showing a lower incidence of severe grade 3-4 acute GVHD in haploidentical HCT.